Concepedia

Author

Kristi A. Boehm

Texas Oncology

Also Known As

K A Boehm, K BOEHM, K Boehm, K. A. Boehm, K. Boehm, K.A. Boehm, Kristi A Boehm, Kristi A. Boehm, Kristi Boehm

94

Publications

3.1K

Citations

26

H-Index

52

Concepts

All Affiliations

Texas OncologyRocky Mountain Cancer CentersThe US Oncology NetworkVirginia Oncology AssociatesMinnesota Oncology
KA

About

Kristi A. Boehm is an author at Texas Oncology specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

20

31

1.1K

2

Health Sciences

10

10

423

3

Natural Sciences

1

1

25

4

Biochemistry

1

1

25

5

Biostatistics

1

1

43

Kristi A. Boehm

×

44

Publications

2.9K

Citations

26

H-Index

YearCitations

Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735

Stephen E. Jones, Frankie A. Holmes, Joyce O’Shaughnessy,

Journal of Clinical Oncology

2009

584

Phase III Trial Comparing Doxorubicin Plus Cyclophosphamide With Docetaxel Plus Cyclophosphamide As Adjuvant Therapy for Operable Breast Cancer

Stephen E. Jones, Michael A. Savin, Frankie A. Holmes,

Journal of Clinical Oncology

2006

537

Randomized Phase III Trial of Gemcitabine-Based Chemotherapy With In Situ RRM1 and ERCC1 Protein Levels for Response Prediction in Non–Small-Cell Lung Cancer

Craig H. Reynolds, Coleman K. Obasaju, Michael J. Schell,

Journal of Clinical Oncology

2009

172

Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy

Guru Sonpavde, Phillip Periman, D. M. Bernold,

Annals of Oncology

2009

137

Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study

David Richards, Kristi A. Boehm, David Waterhouse,

Annals of Oncology

2006

98

Phase II Evaluation of Nanoparticle Albumin–Bound Paclitaxel in Platinum-Sensitive Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer

Michael Teneriello, Paul C. Tseng, Mark Crozier,

Journal of Clinical Oncology

2009

79

Treatment of newly diagnosed and relapsed acute promyelocytic leukemia with intravenous liposomal all-transretinoic acid

Dan Douer, Elihu H. Estey, Sergio Santillana,

Blood

2001

77

Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma

Nicholas Di Bella, Raymond Taetle, Kathryn S. Kolibaba,

Blood

2009

77

Phase III Trial of Cetuximab, Bevacizumab, and 5-Fluorouracil/Leucovorin vs. FOLFOX-Bevacizumab in Colorectal Cancer

Leonard B. Saltz, Suprith Badarinath, Shaker R. Dakhil,

Clinical Colorectal Cancer

2011

69

Effects of LX4211, a Dual Sodium-Dependent Glucose Cotransporters 1 and 2 Inhibitor, on Postprandial Glucose, Insulin, Glucagon-like Peptide 1, and Peptide Tyrosine Tyrosine in a Dose-Timing Study in Healthy Subjects

Brian Zambrowicz, Ike Ogbaa, Kenny Frazier,

Clinical Therapeutics

2013

65

Page 1